The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS) Meeting Abstract
| Authors: | Gounder, M. M.; Wagner, A. J.; Somaiah, N.; Riedel, R. F.; Schwartz, G. K.; Atti, S.; Razak, A. R. A.; Cranmer, L. D.; Okuno, S. H.; Milhem, M. M.; Choe-Juliak, C.; Shacham, S.; Kauffman, M. G.; Chawla, S. P. |
| Abstract Title: | The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLS) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 586s |
| Language: | English |
| ACCESSION: | WOS:000404712500463 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS11072 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS11072 -- Source: Wos |
